Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
216.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Carnival And American Airlines Lead The SPY Higher Tuesday
July 20, 2021
U.S. indices were trading higher Tuesday amid a rebound in reopening stocks, which dipped Monday amid Delta variant concerns. The...
Via
Benzinga
Is It Too Late to Buy Biogen Stock?
July 19, 2021
This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.
Via
The Motley Fool
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...
Via
Benzinga
Exposures
Product Safety
What 18 Analyst Ratings Have To Say About Biogen
July 16, 2021
Within the last quarter, Biogen (NASDAQ:BIIB) has observe...
Via
Benzinga
4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021
July 18, 2021
There are important things to watch with each of these stocks.
Via
The Motley Fool
Exposures
COVID-19
Week In Review: Innocare Strikes $937 Million Deal With Biogen For BTK Inhibitor
July 17, 2021
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Biogen will pay $125 million upfront and up to $812.5 million in milestones, plus royalties.
Via
Talk Markets
Stock Market Rally Struggles Outside Apple; JPMorgan, Goldman, UnitedHealth, Taiwan Semi Are Key Earnings
July 16, 2021
Apple hit record highs, but the stock market quietly struggled this week. JPMorgan, Goldman, Taiwan Semi kicked off earnings.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
July 16, 2021
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday.
Via
Investor's Business Daily
Exposures
Product Safety
Better Biotech Stock: Biogen vs. Annovis Bio
July 16, 2021
Both are making Alzheimer's drugs, but only one can claim success as of today.
Via
The Motley Fool
AMD And Biogen Lead The QQQ Lower Thursday
July 15, 2021
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today
July 15, 2021
BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses.
Via
InvestorPlace
Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration
July 15, 2021
A pair of large hospitals have declined to administer Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s treatment Aduhelm, Wall Street Journal reported. The...
Via
Benzinga
Biogen Stock Dives After Cleveland Clinic, Mount Sinai Ban Alzheimer's Drug Aduhelm
July 15, 2021
Biogen stock tumbled Thursday after the Cleveland Clinic and Mount Sinai said they won't administer the company's Alzheimer's drug, Aduhelm.
Via
Investor's Business Daily
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
July 15, 2021
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ...
Via
Benzinga
Exposures
Product Safety
Biogen Stock And The Aduhelm Drama: Will It Really Treat Alzheimer's?
July 15, 2021
The fate of Biogen stock is now intricately tied to the success — or failure — of its controversial Alzheimer's treatment, Aduhelm.
Via
Investor's Business Daily
US Medicare Starts Coverage Policy Review For Biogen's Aduhelm
July 13, 2021
The U.S. government started a review process for national Medicare coverage of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm. The Centers for...
Via
Benzinga
Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate
July 13, 2021
Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's...
Via
Benzinga
Tesla And Lam Research Lead The QQQ Higher Monday
July 12, 2021
Major U.S. indices managed to all finish with record closing highs Monday as investors continue to weigh last week’s sell-off over conce...
Via
Benzinga
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
July 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
July 11, 2021
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...
Via
Benzinga
Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval
July 09, 2021
Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval.
Via
Investor's Business Daily
Exposures
Product Safety
Biogen Slides As FDA Calls For Investigation Into Approval Of Controversial Alzheimer's Drug
July 09, 2021
Shares of Biogen sank to their lowest levels of the session, weighing on the broader biotech sector.
Via
Talk Markets
Exposures
Product Safety
FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval
July 09, 2021
Biogen Inc. (NASDAQ:BIIB) shares came under pressure Frida...
Via
Benzinga
Exposures
Product Safety
Understanding Biogen's Unusual Options Activity
July 09, 2021
On Friday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $369.73. Sentiment: BULLISH Option Type: SWEEP Trade...
Via
Benzinga
Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More
July 09, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is intrigued about Anavex Life Sciences Corp (NASDAQ: AVXL) because Biogen Inc (NASDAQ: BIIB) data doesn...
Via
Benzinga
Should Biogen Worry About a Congressional Investigation Into Its Alzheimer's Disease Drug?
July 09, 2021
The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.
Via
The Motley Fool
Exposures
Product Safety
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
July 08, 2021
What did the stock market do today? Well, it did a little bit of everything, with short squeezes, crypto gains, IPO hype and regulation fears.
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
Baidu And Nvidia Lead The QQQ Lower Thursday
July 08, 2021
U.S. indices were trading lower Thursday amid concerns the economic recovery is slowing. Growing concerns over the COVID-19 Delta variant have also...
Via
Benzinga
Exposures
COVID-19
Forget a Bear Market -- These 2 Nasdaq Stocks Are Moving Higher
July 08, 2021
Even with markets suffering, there were still some positives on Wall Street.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.